Overall, the expression levels of ITIHs were significantly associated with the clinical stage in the following cancers: LIHC (for ITIH1-ITIH4), KIRC (for ITIH1, ITIH3, and ITIH4), KIRP (for ITIH2 and ITIH4), LUSC (for ITIH2 and ITIH4), STAD (for ITIH3 and ITIH5), PAAD (for ITIH1), cervical squamous cell carcinoma (CESC) (for ITIH4), ovarian serous cystadenocarcinoma (OV) (for ITIH4), adrenocortical carcinoma (ACC) (for ITIH5), BRCA (for ITIH5), and LUAD (for ITIH5) (Figure 3 and Supplementary Figure 9). This evidence concerns the gene ITIH3 and adrenal cortex carcinoma.